

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute any invitation or offer to acquire, purchase or subscribe for any securities.



杭州启明醫療器械股份有限公司

Venus Medtech (Hangzhou) Inc.

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2500)

VOLUNTARY ANNOUNCEMENT ESTABLISH VENUS GLOBAL HEART VALVE INNOVATION CENTER

This announcement is made by Venus Medtech (Hangzhou) Inc. (the “**Company**”) on a voluntary basis. The board of directors of the Company (the “**Board**”) is pleased to announce that the Venus Global Heart Valve Innovation Center will be established in Israel and Mr. Amir Gross will be appointed as the head of the Venus Global Heart Valve Innovation Center. Mr. Amir Gross is the chief executive officer of Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter mitral and tricuspid valve treatment company, which was 100% acquired by the Company in January 2022. For details of the completion of acquisition of Cardiovalve, please refer to the announcement of the Company dated January 26, 2022.

To further improve the Company’s global innovation system and product portfolio, the Venus Global Heart Valve Innovation Center will be the hub for the incubation of breakthrough innovative therapeutic technologies, focusing on including the development of a new generation of technologies for the treatment of aortic regurgitation by taking advantage of the Cardiovalve technology platform and application of digital health technology to the valve system, with technologies transfer to China and other regions of the world at a proper time. At the same time, the Company will also activate the Venus Global Heart Valve Innovation Center to undertake the exchange and training program of Chinese and Israeli engineers, which will better cultivate innovative talents with the exceptional resources of both countries so as to lay a solid foundation for long-term development.

The Board believes that the establishment of the Venus Global Heart Valve Innovation Center will accelerate the international footprint of the Company's innovation system and provide high-value medical devices for clinicians and patients.

By order of the Board
Venus Medtech (Hangzhou) Inc.
Min Frank Zeng
Chairman

Hangzhou, March 1, 2022

As at the date of this announcement, the executive Directors are Mr. Min Frank Zeng, Mr. Zhenjun Zi and Mr. Lim Hou-Sen (Lin Haosheng); the non-executive Director is Ms. Nisa Bernice Wing-Yu Leung; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu, Mr. Wan Yee Joseph Lau and Mr. Chi Wai Suen.